Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Child and Adolescent Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 12, 2008
Neuronal nicotinic receptor agonists potential breakthrough for ADHD research
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
1. Effective treatment for ADHD 2. Well tolerated with few side effects 3. Help with smoking, a big problem in ADHD patients important 4. Advantage in not being Schedule II may be helpful
May 12, 2008
Important New Data for Children and Adolescents
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial
March 7, 2008
Exciting new treatment for OCD and Social Anxiety Disorder
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
1. Controlled release preparations are often better tolerated with fewer side effects than immediate release preparations 2. OCD and SAD are severe, highly prevalent and chronically disabling conditions 3. Despite presence of SSRIs and other treatment, e.g, cognitive behavioral therapy, up to 1/3 of...
March 7, 2008
FDA Approval of Abilify for Pediatric Bipolar disorder is a Major Advance
Analysis of: U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) | pharmalive.com
Author: GLG Expert Contributor
1. Despite common use of multiple psychotropic medications for bipolar disorder in youth, there are few FDA-approved treatments 2. Abilify is one of the safest and best tolerated of the atypical antipsychotics with fewer side effects than some of the other atypical antipsychotic medications 3. This...
February 5, 2008
More questions raised than answers
Analysis of: Chantix And Suicide: The Latest Numbers | www.pharmalot.com
Author: GLG Expert Contributor
No good data that Chantix is associated with suicide Need more controlled research to answer questions Scary adverse events are not the same as side effects directly linked to medication
October 11, 2007
Vanda"s Iloperidone: Lemonade or Lemon
Analysis of: Vanda Pharmaceuticals Submits Iloperidone New Drug Application | www.pipelinereview.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. Iloperidone has demonstrated efficacy in treating positive and negative symptoms of schizophrenia and also has a favorable safety profile. 2. Vanda has utilized pharmacogenetic studies to identify a group of schizophrenic patients that will benefit from this agent that binds to a number of serotonin...
October 8, 2007
DOV 21,947: A Triple Reuptake Inhibitor With a Favorable Metabolic Profile
Analysis of: DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study | www.medicalnewstoday.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. DOV 21,947 in a phase Ib study produced a statistically significant reduction in plasma triglyceride levels, body weight, and Body Mass Index (BMI). 2. This compound is believed to not only manage depression but also impact weight gain. 3. A phase II study of DOV 21,947 is being delayed until the...
September 18, 2007
Shire Takes Proactive Stance Regarding Daytrana Skin Patches
Analysis of: Shire withdraws some ADHD skin patches | www.reuters.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. Shire has withdrawn patches that had defective patch liners. 2. This defect is not related to safety or efficacy issues. 3. The cost to Shire is less than $10 million.
September 12, 2007
New Potentially Effective Antidepressants to be Marketed by a Potentially Effective Alliance
Analysis of: Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds in the US and Japan for the Treatment of Mood and Anxiety Disorders | www.pipelinereview.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. Lu AA21004 and Lu AA24530 are two compounds with a great deal of potential and will be co-marketed jointly by Takeda and Lundbeck. 2. Lu AA21004 is the more advanced of the compounds and is currently in phase II development for the treatment of major depression. 3. The compounds potentially address...
September 11, 2007
LY2140023: An Antipsychotic With A New Mechanism of Action
Analysis of: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds | www.pipelinereview.com
Author: Lawrence Ginsberg, President, Red Oak Psychiatry Associates, P. A.
1. LY2140023 is an antipsychotic agent that is a metabotropic glutamate 2/3 receptor agonist. This agent has a new mechanism of action that is efficacious in treating schizophrenia and potentially other neuropsychiatric conditions. 2. LY2140023 in addition to separating from placebo in a statistically...

Page : 1 2 3 4 5 6 Next1 to 10 of 54

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773